EvanJacobLipsonMD

Oncology • Baltimore, MD

Melanoma

Associate Professor of Oncology, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Lipson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lipson's full profile

Already have an account?

Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
Icahn School of Medicine at Mount SinaiClass of 2005

Certifications & Licensure

FL State Medical License 2022 - Present
DC State Medical License 2012 - 2026
MD State Medical License 2008 - 2026
PA State Medical License 2024 - 2026
VA State Medical License 2021 - 2026
DE State Medical License 2022 - 2023
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Start of enrollment: 2018 Nov 27
Recruiting
Phase 2
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Start of enrollment: 2019 Nov 08
Active, not recruiting
Phase 1
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Start of enrollment: 2024 Aug 11
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Targeting molecular pathways to control immune checkpoint inhibitor toxicities.
Robin Reschke, Ryan J Sullivan, Evan J Lipson, Alexander H Enk, Thomas F Gajewski
Trends in Immunology. 2024-12-27
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, Dirk Schadendorf, Paolo A Ascierto
Journal of Clinical Oncology. 2024-12-13
4 citations
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Tri...
Georgina V Long, Evan J Lipson, F Stephen Hodi, Paolo A Ascierto, James Larkin
Journal of Clinical Oncology. 2024-11-20

Journal Articles

From Validity to Clinical Utility: The Influence of Circulating Tumor DNA on Melanoma Patient Management in a Real‐World Setting
Karen B Bleich, William H Sharfman, Steven P Rowe, Evan J Lipson, Megan D Schollenberger, Molecular Oncology
Nodular Regenerative Hyperplasia Associated with Immune Checkpoint Blockade
Evan J Lipson, Michael I Brener, Jaclyn LoPiccolo, James P Hamilton, Hepatology

Press Mentions

Toxic Trade-OffsMarch 16th, 2023
Evan Lipson, MD, on Nivolumab plus Relatlimab for Advanced MelanomaJuly 14th, 2022
ASCO: Nivolumab, Relatlimab Combo Slows Advanced MelanomaMay 30th, 2021
Join now to see all

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/evan-lipson